Fig. 6
Combined neoadjuvant antitumor effect of SFV-IL-12 and LVR01. One dose of SFV-IL-12 or SFV-LacZ (2×108 vp in 50 μl PBS), or LVR01 (2×107 cfu in 50 μl PBS), or 50 μl PBS was i.t. injected at days 10 and/or 13 after 4 T1 cells inoculation. In most groups, treated tumors were surgically removed at day 16 (S-16). a Schematic representation of the therapeutic protocol for the combinations relevant to this study. b Kaplan–Meier plot shows the survival rate of the indicated groups of mice. The total number of animals included in the SFV-IL-12 + LVR01 + S-16 group was 31 (consecutive experiments) and the 28 survivor mice were employed in the re-challenge study presented in Fig. 8. For the rest of the groups n = 8-10. c Tumor size was measured before surgery (day 16) and mean + SD tumor volumes were calculated for each group. d Representative images of treated tumors excised 16 days after 4 T1 cells inoculation. p< 0.05 (*); p< 0.01 (**); p< 0.001 (***)